Contact PI/Project LeaderOFOTOKUN, IGHOVWERHA Other PIs
Awardee OrganizationEMORY UNIVERSITY
Description
Abstract Text
Project Summary/Abstract
The currently funded Emory-CDC Clinical Trials Unit (Emory-CDC CTU) is ideally positioned to
implement the mission of
NIAID and to conduct clinical trials developed by the NIH HIV/AIDS
Clinical TrialsNetworks.
The Emory-CDC CTU is supported by Emory’s rich scientific milieu
with numerous synergistic grants and various thematic research centers covering all network
priority areas, as well as the support and experience of our CDC partners. The Emory-CDC
CTU is comprised of 5 CRSs with well-established programs and histories of performing NIH
funded clinical research. In this renewal the Emory-CDC CTU will be expanding to a 6th CRS in
Mexico City. Our specific aims are the following:
1. To contribute scientific expertise and human subject enrollment into studies that address
these four key research areas: Adult HIV therapeutic strategies, including HIV cure,
noninfectious comorbidities, and the infectious comorbidities of hepatitis and
tuberculosis; strategies to address HIV and HIV-associated infections in pediatric and
maternal populations; integrated HIV prevention strategies; and vaccines to prevent HIV
infection.
2. To be a leading CTU for contributions of women, minorities, and adolescents to support
network clinical trials, both domestically and in low and middle-income countries.
3. To operate an efficient and flexible CTU that can respond rapidly to evolving research
opportunities.
4. To participate in the development and implementation of the clinical research plans of all
the NIAID clinical research networks that are addressing the four priority areas.
Public Health Relevance Statement
Project Narrative
The Emory-CDC Clinical Trials Unit is well positioned to contribute to the mission of
the NIH
HIV/AIDS Clinical TrialsNetworks due to our
extensive experience in conducting clinical trials
related to Hepatitis/TB/HIV vaccine, prevention, and treatment both domestically and
internationally. We are well suited to participate in pediatric maternal and adult populations.
Through our partnerships with the CDC, and our diverse scientific collaborators, we are poised
to help develop and implement the next generation of network research plans.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAcquired Immunodeficiency SyndromeAddressAdolescentAdultAnti-Retroviral AgentsAreaBiological ProductsCenters for Disease Control and Prevention (U.S.)ChildhoodCitiesClinicClinical ResearchClinical TrialsClinical TrialsNetworkClinical Trials UnitCollaborationsComplexConduct Clinical TrialsCountryDevelopmentDiseaseDisease remissionEnrollmentEpidemicFundingGrantHIVHIV InfectionsHIV therapyHIV vaccineHIV/AIDSHIV/TBHepatitisInfectionInflammationInstitutionInternationalInterventionKenyaLatino menMalignant NeoplasmsMethodsMexicoMinorityMissionNational Institute of Allergy and Infectious DiseaseNetwork InfrastructureOpportunistic InfectionsOrganPharmaceutical PreparationsPhilippinesPopulationPopulation HeterogeneityPositioning AttributePreventionPrevention strategyPrimatesProductivityProtocols documentationPublic PolicyRecording of previous eventsResearchResearch ActivityResearch InfrastructureResearch PersonnelResearch SubjectsScientific Advances and AccomplishmentsSiteSocial BehaviorStrategic PlanningTechnologyThailandTherapeuticTranslatingTranslational ResearchTuberculosisTuberculosis VaccinesUnderrepresented PopulationsUnited States National Institutes of HealthUniversitiesVaccinesWomanYouthclinical centerclinical implementationclinical research siteco-infectioncomorbidityexperienceflexibilityhigh riskhuman subjectimprovedlow and middle-income countriesmembernext generationnovelpreventprogramsrecruitsuccesssupport networktherapeutic vaccinetreatment strategytuberculosis treatmentvaccine developmentvolunteerworking group
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
01-February-2007
Project End Date
30-November-2027
Budget Start Date
01-December-2024
Budget End Date
30-November-2025
Project Funding Information for 2025
Total Funding
$1,855,823
Direct Costs
$1,458,532
Indirect Costs
$397,291
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$1,855,823
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UM1AI069418-19
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UM1AI069418-19
Patents
No Patents information available for 5UM1AI069418-19
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UM1AI069418-19
Clinical Studies
No Clinical Studies information available for 5UM1AI069418-19
News and More
Related News Releases
No news release information available for 5UM1AI069418-19
History
No Historical information available for 5UM1AI069418-19
Similar Projects
No Similar Projects information available for 5UM1AI069418-19